Form 8-K Viking Therapeutics, For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Citi Starts Viking Therapeutic (VKTX) at Neutral
February 7, 2025 6:52 AM ESTCiti analyst David Lebowitz initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Neutral rating and a price target of $38.00.
The analyst comments "The relatively recent emergence of GLP-1s for the treatment of obesity has rapidly established a megamarket opportunity... More
Viking Therapeutic (VKTX) PT Lowered to $95 at Truist Securities
February 6, 2025 12:07 PM ESTTruist Securities analyst Joon Lee lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $95.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "4Q24 update narrowed timeline for the start of 2x Ph3 studies of SQVK2735 in obesity. Toplines from Ph3... More
